BioMarin Pharmaceutical Inc. (BMRN)

Market Cap	11.92B
Revenue (ttm)	2.75B
Net Income (ttm)	322.29M
Shares Out	190.58M
EPS (ttm)	1.68
PE Ratio	37.23
Forward PE	17.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,142,877
Open	61.97
Previous Close	61.97
Day's Range	61.61 - 62.70
52-Week Range	61.15 - 99.56
Beta	0.31
Analysts	Buy
Price Target	94.20 (+50.58%)
Earnings Date	Oct 29, 2024

About BMRN

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inher...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 1999
• Employees: 3,401
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRN
• Website: https://www.biomarin.com

Financial Performance

In 2023, BioMarin Pharmaceutical's revenue was $2.42 billion, an increase of 15.42% compared to the previous year's $2.10 billion. Earnings were $167.65 million, an increase of 18.43%.

Analyst Forecast

According to 21 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $94.2, which is an increase of 50.58% from the latest price.

Price Target

$94.2

(50.58% upside)

Analyst Consensus: Buy